Omega Diagnostics Group PLC Heads of Terms agreed for Sale of CD4 Business (1199R)

TIDMODX

RNS Number : 1199R

Omega Diagnostics Group PLC

04 July 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Heads of Terms agreed for Sale of CD4 Manufacturing Business

In-line with strategic plan to focus on higher growth Health & Nutrition division

Further to the Circular published on the 13 May 2022 indicating that the Group's CD4 business was being marketed for sale, Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that after receiving a number of indicative offers, the Company has now selected a preferred bidder to acquire its CD4 business. On 2 July 2022, Omega and the preferred bidder signed Heads of Terms in relation to the sale of the Company's CD4 business, which manufactures and supplies VISITECT(R) CD4 and VISITECT(R) CD4 Advanced Disease tests (the "CD4 Business").

The preferred bidder has now been granted four weeks in which to complete the remainder of their due diligence, which mainly comprises commercial discussions of a confirmatory nature with key customers and suppliers. The transaction is expected to complete shortly thereafter and will include a significant up-front cash payment and a future royalty stream linked to VISITECT(R) CD4 test sales.

As previously indicated the Board believes the CD4 Business will be more successful under new ownership, with an owner which has a greater capacity to invest in production capabilities and product development. The Company will now focus solely on its Health & Nutrition business, where there are significant growth opportunities.

Recognising the future funding requirements of the Group will change significantly following the divestment of the CD4 Business, Bank of Scotland has agreed to extend the existing overdraft facility of GBP2.0 million by an additional three months, to 30 September 2022. This allows Omega sufficient time to reassess the funding requirement for its profitable and higher growth Health & Nutrition division.

Jag Grewal, CEO of Omega, commented: "We were delighted by the level of interest we have received for the CD4 business and look forward to announcing the completion of the transaction in due course. Having withdrawn from the COVID-19 market and disposed of the Alva site earlier this year, the divestment of our loss-making CD4 business will leave the Group solely focused on our higher margin Health & Nutrition division. The net proceeds from the sale of the CD4 Business will enable our product and geographical expansion ambitions to be realised."

Contacts:

 
 Omega Diagnostics Group PLC                                       www.omegadx.com 
 Jag Grewal, Chief Executive Officer                               via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 
 finnCap Ltd                                                    Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore 
  (Corporate Finance) 
 Alice Lane/ Harriet Ward (ECM) 
 
 Walbrook PR Limited                    Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                   Mob: 07980 541 893 
 Lianne Applegarth                                              Mob: 07584 391 303 
 Sam Allen                                                      Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DISMZGGNLFZGZZM

(END) Dow Jones Newswires

July 04, 2022 02:00 ET (06:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2024 to Apr 2024